Glenmark Specialty S.A. has officially launched Winlevi (clascoterone 10 mg/g cream) across key European markets, including Spain, Portugal, and the Nordic region. The rollout represents the company's first New Chemical Entity (NCE) launch in Europe, introducing an innovative topical acne therapy that targets skin-level androgen receptors.
MUMBAI — Mumbai-headquartered global pharmaceutical manufacturer Glenmark Pharmaceuticals Limited, through its wholly-owned subsidiary Glenmark Specialty S.A., announced on Thursday, June 11, 2026, the official commercial launch of its first-in-class acne treatment, Winlevi (clascoterone 10 mg/g cream), across major European markets.
The strategic rollout represents a significant operational milestone for the company, introducing the first topical mechanism of action for acne vulgaris in the region in over 40 years. By launching direct commercial configurations in Spain, the Nordic countries, and parts of Central and Eastern Europe, the research-led drugmaker is moving forward with its planned transition away from commoditized generics and toward high-entry-barrier specialty pharmaceutical assets.
Direct and Partnered Distribution Across the European Union
According to regulatory filings submitted directly to the National Stock Exchange of India (NSE), the company has established a dual-track commercialization layout to ensure rapid region-wide delivery.
Glenmark has initiated direct sales and marketing operations across high-volume territories, including Spain, Denmark, Finland, Norway, and Sweden. Concurrently, the firm has deployed a strategic partner network to handle localized distribution loops in other specific member states, formally launching the product in Portugal through an established regional collaborator this morning.
The commercial rollout follows a formal licensing and co-development agreement with Irish life sciences firm Cosmo Pharmaceuticals N.V. and its subsidiary Cassiopea S.p.A. While Cassiopea maintains the primary European marketing authorizations granted by the European Commission, Glenmark holds the exclusive commercialization and prescription distribution rights across a consolidated footprint spanning 15 to 17 European nations.
Targeting Hormonal Pathways via a New Chemical Entity
Dermatological tracking data indicates that acne vulgaris stands as one of the most widespread skin conditions globally, affecting more than 95% of males and 85% of females during adolescence, with 50% of patients continuing to experience symptoms well into adulthood.
The commercial availability of Winlevi introduces a New Chemical Entity (NCE) designed specifically to address the root hormonal causes of skin inflammation, contrasting with older, traditional treatments:
By directly blocking skin-level androgen receptors, clascoterone limits the production of excess sebum (protective skin oils) and reduces inflammatory pathways without introducing systemic hormonal imbalances.
According to guidelines approved by the European Medicines Agency (EMA), the drug is cleared for the treatment of acne vulgaris in adults, as well as facial acne vulgaris in adolescents aged 12 to 18 years, with a standard recommended clinical regimen of a thin, uniform application twice daily.
Official Sources Section
Regulatory filings, product specifications, clinical indications, and geographic launch frameworks are prepared in strict accordance with statutory corporate announcements uploaded to the BSE, official press releases published by Glenmark Specialty S.A., and drug evaluation summary sheets maintained by the European Medicines Agency (EMA).
Quote Section
Glenmark’s leadership emphasized that the launch validates the company's long-term strategy to expand its presence within the high-margin international specialty dermatology sector.
According to Christoph Stoller, President and Business Head of Europe and Emerging Markets at Glenmark Pharmaceuticals:
"The commercial launch of Winlevi in key European markets is a defining moment in executing our mission to become a research-led, global pharmaceutical entity. As our first New Chemical Entity launch in Europe, Winlevi strengthens our established dermatology footprint across the region, and we remain dedicated to ensuring patients secure timely access in full alignment with local healthcare frameworks."
Commenting on the structural benefits for healthcare providers, clinical research leads added:
"The dermatology community has relied on variations of standard antibiotics, benzoyl peroxide, and retinoids for decades. Bringing a topical androgen receptor inhibitor into European clinics offers dermatologists a highly effective, non-antibiotic tool to address underlying hormonal triggers directly at the skin site."
Why It Matters
For millions of patients across Europe navigating the physical and psychological challenges of persistent acne, the introduction of a fresh therapeutic pathway offers a vital alternative when traditional antibiotic or systemic retinoid treatments prove ineffective or introduce intolerable side effects.
From an investment and corporate perspective, Glenmark’s successful transition into NCE commercialization in Europe helps insulate the company's balance sheet from the severe pricing pressures currently impacting the US generics market. This strategic shift is expected to support improved long-term operating margins and enhance the company's market valuation relative to its specialty pharmaceutical peers.
Key Facts at a Glance
The Launch: Glenmark has officially commercialized the innovative acne cream Winlevi across major European markets, including Spain and the Nordic region.
First-in-Class Status: Winlevi (clascoterone 10 mg/g) represents the first topical acne treatment featuring a new mechanism of action approved in Europe in over 40 years.
Corporate Milestone: The rollout marks Glenmark’s inaugural launch of a New Chemical Entity (NCE) within the European continent.
Patient Demographics: The product is clinically cleared for adults and adolescents aged 12 years and older, with adolescent use focused on facial applications.
FAQ Section
How does Winlevi differ from traditional topical acne treatments?
Unlike standard topical antibiotics that target bacteria or retinoids that focus on skin cell turnover, Winlevi contains clascoterone. This active ingredient blocks androgen receptors directly in the skin, reducing the excess oil production that triggers acne.
Which European countries have access to Winlevi through this launch?
Direct commercial launches are active across Spain, Sweden, Denmark, Norway, and Finland, alongside a partnered launch in Portugal. Rollouts across Central and Eastern European hubs are progressing in phases.
Are there any specific safety guidelines or age limits for using Winlevi?
The cream is authorized for adults and adolescents aged 12 and older. EMA guidelines state it should be applied to clean, dry skin twice daily, and adolescents must limit usage strictly to facial areas.
Source: National Stock Exchange of India (NSE) Corporate Submissions, European Medicines Agency (EMA) Product Information Portal, Glenmark Investor Relations Division, Cosmo Pharmaceuticals N.V. Corporate Communications.
